Role of Teriparatide in Treatment of Glucocorticoid-induced Osteoporosis

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2010 Nov 11

PMID 21063460

Citations 2

Authors

Arthur N Lau

Jonathan D Adachi

Affiliations

Soon will be listed here.

Abstract

Glucocorticoids are commonly used in various fields within medicine. One of their most common and clinically significant side effects is glucocorticoid-induced osteoporosis (GIOP). GIOP is a disease leading to progressive decreases in bone mineral density, decreased bone strength, and increased risk of skeletal fractures. GIOP has a significant impact on the morbidity and health-related quality of life of the patients it affects. Glucocorticoids have deleterious effects on bone through promoting osteoblast apoptosis and inhibiting osteoblastogenesis. Teriparatide exerts anabolic effects on bone, so it is understandable why teriparatide is thought to be a rational treatment option. Clinical studies have indicated teriparatide is efficacious in the treatment of GIOP to improve bone mineral density values at the lumbar spine and femoral neck. Some evidence also suggests teriparatide may reduce rates of vertebral fractures in GIOP patients. Overall, this review of the current clinical evidence suggests teriparatide may be an efficacious and promising agent in the treatment of GIOP.

Citing Articles

Bisphosphonate-related osteonecrosis of the jaw: specificities.

Paulo S, Abrantes A, Laranjo M, Carvalho L, Serra A, Botelho M Oncol Rev. 2015; 8(2):254.

PMID: 25992241 PMC: 4419650. DOI: 10.4081/oncol.2014.254.

Recognizing and treating secondary osteoporosis.

Walker-Bone K Nat Rev Rheumatol. 2012; 8(8):480-92.

PMID: 22782006 DOI: 10.1038/nrrheum.2012.93.

References

Abadie E, Devogealer J, Ringe J, Ethgen D, Bouvenot G, Kreutz G . Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Semin Arthritis Rheum. 2005; 35(1):1-4. DOI: 10.1016/j.semarthrit.2005.03.006. View

Dempster D, Cosman F, Parisien M, Shen V, Lindsay R . Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993; 14(6):690-709. DOI: 10.1210/edrv-14-6-690. View

Compston J . US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. Curr Rheumatol Rep. 2004; 6(1):66-9. DOI: 10.1007/s11926-004-0085-1. View

Benhamou C . Effects of osteoporosis medications on bone quality. Joint Bone Spine. 2007; 74(1):39-47. DOI: 10.1016/j.jbspin.2006.06.004. View

Roger L . Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritis. Am J Med. 1995; 99(6):692-4. DOI: 10.1016/s0002-9343(99)80264-2. View

Krishnan V, Bryant H, MacDougald O . Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116(5):1202-9. PMC: 1451219. DOI: 10.1172/JCI28551. View

OBrien C, Jia D, Plotkin L, Bellido T, Powers C, Stewart S . Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2003; 145(4):1835-41. DOI: 10.1210/en.2003-0990. View

Canalis E . Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep. 2005; 3(3):98-102. DOI: 10.1007/s11914-005-0017-7. View

Adachi J, Bensen W, Bianchi F, Cividino A, Pillersdorf S, Sebaldt R . Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol. 1996; 23(6):995-1000. View

10.

van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C . Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6):993-1000. DOI: 10.1359/jbmr.2000.15.6.993. View

11.

Canalis E, Bilezikian J, Angeli A, Giustina A . Perspectives on glucocorticoid-induced osteoporosis. Bone. 2004; 34(4):593-8. DOI: 10.1016/j.bone.2003.11.026. View

12.

Nevitt M, Chen P, Dore R, Reginster J, Kiel D, Zanchetta J . Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int. 2005; 17(2):273-80. DOI: 10.1007/s00198-005-2013-2. View

13.

Miller P . Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008; 6(1):12-6. DOI: 10.1007/s11914-008-0003-y. View

14.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

15.

Saag K, Zanchetta J, Devogelaer J, Adler R, Eastell R, See K . Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11):3346-55. DOI: 10.1002/art.24879. View

16.

Giusti A, Hamdy N, Papapoulos S . Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone. 2010; 47(2):169-80. DOI: 10.1016/j.bone.2010.05.019. View

17.

Chen P, Miller P, Delmas P, Misurski D, Krege J . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21(11):1785-90. DOI: 10.1359/jbmr.060802. View

18.

van Staa T, Leufkens H, Cooper C . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13(10):777-87. DOI: 10.1007/s001980200108. View

19.

Lane N, Sanchez S, Modin G, Genant H, Pierini E, Arnaud C . Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000; 15(5):944-51. DOI: 10.1359/jbmr.2000.15.5.944. View

20.

Devogelaer J, Adler R, Recknor C, See K, Warner M, Wong M . Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol. 2009; 37(1):141-8. DOI: 10.3899/jrheum.090411. View